News AC Immune SA

Equities

ACIU

CH0329023102

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:57:23 2026-05-21 am EDT			5-day change	1st Jan Change
2.805 ^USD	-2.94%		-0.18%	-10.99%

May. 15	AC Immune SA Announces Retirement of Andrea Pfeifer as CEO	CI
May. 12	AC Immune CEO Andrea Pfeifer to Retire	MT

All News

Mentions Relevance

May. 15	AC Immune SA Announces Retirement of Andrea Pfeifer as CEO	CI
May. 12	AC Immune CEO Andrea Pfeifer to Retire	MT
May. 12	AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM	AQ
May. 12	AC Immune SA Announces Executive Changes	CI
Apr. 30	AC Immune: Q1 Earnings Snapshot	AQ
Apr. 30	AC Immune First Quarter 2026 Financial and Corporate Updates	AQ
Apr. 30	AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease	AQ
Apr. 30	AC Immune SA Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease	CI
Apr. 07	AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly	AQ
Apr. 07	AC Immune Extends Alzheimer's Drug Pact With Eli Lilly	DJ
Apr. 07	AC Immune, Eli Lilly Amend Morphomer Tau License, Collaboration Agreement; Shares Up Pre-Bell	MT
Apr. 07	AC Immune announces amendment to Morphomer® tau license and collaboration agreement with Lilly	RE
Apr. 07	AC Immune SA and Eli Lilly Amend Tau Morphomer Collaboration Agreement	CI
Mar. 19	AC Immune presents first in vivo images of brain TDP-43 pathology from Phase 1 trial of PET tracer ACI-19626, at AD/PDTM 2026	RE
Mar. 19	AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026	AQ
Mar. 19	Ac Immune Sa Presents First in Vivo Images of Brain Tdp-43 Pathology from Phase 1 Trial of Pet Tracer Aci-19626	CI
Mar. 13	AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 13	AC Immune: Q4 Earnings Snapshot	AQ
Mar. 13	AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update	AQ
Mar. 06	AC Immune Announces Upcoming Industry Symposium on Parkinson's disease and Presentation at AD/PD 2026	AQ
Mar. 05	AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026	AQ
Feb. 24	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor	CI
Feb. 24	AC Immune initiates phase 1 clinical trial of NLRP3 inhibitor	RE
Feb. 24	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor	AQ